Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Ocuphire Pharma's annualizedGross Profit for the quarter that ended in Mar. 2024 was $6.84 Mil.
Ocuphire Pharma's average Total Assets over the quarter that ended in Mar. 2024 was $52.90 Mil. Therefore, Ocuphire Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 12.94%.
Ocuphire Pharma Gross-Profit-to-Asset % Historical Data
The historical data trend for Ocuphire Pharma's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ocuphire Pharma's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Ocuphire Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocuphire Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocuphire Pharma's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Ocuphire Pharma's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Ocuphire Pharma Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Ocuphire Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocuphire Pharma (Ocuphire Pharma) Business Description
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCUP has been successfully added to your 